Novo Nordisk’s Strategic Pivot: Can a Higher-Dose Wegovy Offset Alzheimer’s Setback?
Published on 11/30/2025 at 03:44 | Redaktion boerse-global.de
Following a punishing week for its share price, Novo Nordisk has launched a strategic counteroffensive. The Danish pharmaceutical giant, still reeling from a significant clinical trial failure, is fighting back with a major regulatory move. The central question for investors is whether a new, higher-dose formulation of its weight-loss drug Wegovy can restore market confidence, or if this represents merely a temporary diversion from deeper challenges.
In a swift response to recent pressures, Novo Nordisk disclosed on Friday, November 28, that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration. The application seeks approval for a 7.2 mg dosage of Wegovy, a substantial increase from Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
